StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)

Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –

TG Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

TG Therapeutics's EV/EBITDA was 74.7× on Nov 11, 2026, against 50.9× a year earlier. Over the last 3 years it ranged from 34.4× to 167.3×, with a median of 60.7×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202674.7×+29.1
2025Dec 31, 202545.6×+8.7
2024Oct 31, 202436.9×–

More TG Therapeutics figures

See a number that looks wrong?